Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 12;11(2):471. doi: 10.3390/nano11020471

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Antitumor effects of aCTLA-4+aPD-1 containing F127/PEG hydrogels in vivo. (A) Tumor size after one administration of saline, free aCTLA-4+aPD-1 (30 or 50 μg total dose of each monoclonal antibody (mAb) clone), or aCTLA-4+aPD-1 (30 or 50 μg total dose of each mAb clone) containing F127/PEG hydrogels injected intradermally (i.d.) into the tissue ipsilateral (i.l.) to the tumor on day 10. (B) Aspartate aminotransferase (AST) and (C) alanine aminotransferase (ALT) in blood 2 d after treatment of 50 μg aCTLA-4+aPD-1. (A) was analyzed with two-way ANOVA. (B) and (C) were analyzed with one-way ANOVA. **** p < 0.0001 and * p < 0.05.